dc.date.accessioned | 2019-12-06T21:04:52Z | |
dc.date.available | 2019-12-06T21:04:52Z | |
dc.date.created | 2019-12-06T21:04:52Z | |
dc.date.issued | 2019 | |
dc.identifier | https://hdl.handle.net/20.500.12866/7654 | |
dc.identifier | https://doi.org/10.1007/s10815-019-01551-5 | |
dc.description.abstract | Purpose: To investigate the effectiveness of a biphasic IVM culture strategy at improving IVM outcomes in oocytes from small follicles (< 6 mm) compared with routine Standard IVM in patients with polycystic ovaries. Methods: This prospective pilot study was performed in 40 women with polycystic ovaries whose oocytes were randomized to two IVM culture methods. Patients received a total stimulation dose of 450 IU rFSH. Cumulus-oocyte complexes (COCs) from follicles < 6 mm and ≥ 6 mm were retrieved and cultured separately in either a prematuration medium with c-type natriuretic peptide followed by IVM (CAPA-IVM), or STD-IVM. Primary outcomes were maturation rate, embryo quality, and the number of vitrified day 3 embryos per patient. Results: Use of the CAPA-IVM system led to a significant improvement in oocyte maturation (p < 0.05), to a doubling in percentage of good and top-quality day 3 embryos per COC, and to an increased number of vitrified day 3 embryos (p < 0.001), compared to STD IVM. Oocytes from follicles < 6 mm benefited most from CAPA-IVM, showing a significant increase in the amount of good and top-quality embryos compared to STD IVM. CAPA-IVM yielded significantly (p < 0.0001) less GV-arrested oocytes and larger oocyte diameters (p < 0.05) than STD IVM. Conclusions: CAPA-IVM brings significant improvements in maturation and embryological outcomes, most notably to oocytes from small antral follicles (< 6 mm), which can be easily retrieved from patients with a minimal ovarian stimulation. The study demonstrates the robustness and transferability of the CAPA-IVM method across laboratories and populations. | |
dc.language | eng | |
dc.publisher | Springer | |
dc.relation | Journal of Assisted Reproduction and Genetics | |
dc.relation | 1573-7330 | |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.subject | human | |
dc.subject | embryo | |
dc.subject | IVM | |
dc.subject | priority journal | |
dc.subject | Article | |
dc.subject | controlled study | |
dc.subject | female | |
dc.subject | human cell | |
dc.subject | adult | |
dc.subject | clinical outcome | |
dc.subject | prospective study | |
dc.subject | clinical article | |
dc.subject | antral follicle | |
dc.subject | C-type natriuretic peptide | |
dc.subject | cell count | |
dc.subject | cell size | |
dc.subject | Embryo | |
dc.subject | in vitro oocyte maturation | |
dc.subject | IVF | |
dc.subject | natriuretic peptide type C | |
dc.subject | oocyte development | |
dc.subject | Oocyte prematuration | |
dc.subject | ovary polycystic disease | |
dc.subject | recombinant follitropin | |
dc.subject | vitrification | |
dc.title | Biphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles | |
dc.type | info:eu-repo/semantics/article | |